Results 131 to 140 of about 147,755 (251)
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs. [PDF]
Villarroya F, Peyrou M, Giralt M.
europepmc +1 more source
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó +84 more
wiley +1 more source
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola +14 more
wiley +1 more source
Objective Identification of osteoarthritis (OA)–specific synovial inflammatory pathways and their temporal relevance is critical for therapeutic targeting. We compared mononuclear inflammatory/immune cell responses following joint injury that does or does not lead to OA to define bona fide OA‐associated cellular events.
Babak Moradi +10 more
wiley +1 more source
Effects of Brown Rice, Meal Replacements, and Anti-Obesity Drugs on Mitochondria in Obese Rats. [PDF]
Handayani D +5 more
europepmc +1 more source
Clock Genes Regulate Ca2+ Signaling and Mitochondrial Bioenergetics to Inhibit Sjögren Disease
Objective Although Ca2+ signaling and metabolism have been identified as key determinants for the development of Sjögren disease (SjD), the intricate connection between them and salivary gland physiology remains poorly understood. Methods Fluorescence‐based Ca2+ imaging, RNA sequencing, and mitochondrial activity were used to investigate the effects of
Viktor R. Drel +12 more
wiley +1 more source
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. [PDF]
Concepción-Zavaleta MJ +9 more
europepmc +1 more source
Can anti-obesity drugs be repurposed to treat cocaine addiction? [PDF]
Reiner DJ, Bossert JM.
europepmc +1 more source
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf +15 more
wiley +1 more source
Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. [PDF]
Seijas-Amigo J +6 more
europepmc +1 more source

